Unison Advisors’s Myriad Genetics MYGN Stock Holding History

Unison Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-13,276	Closed	-$369K	–	181
2019 Q2	$369K	Hold	13,276	–	–	0.28%	86
2019 Q1	$441K	Hold	13,276	–	–	0.33%	80
2018 Q4	$385K	Hold	13,276	–	–	0.31%	81
2018 Q3	$611K	Hold	13,276	–	–	0.43%	70
2018 Q2	$496K	Hold	13,276	–	–	0.36%	75
2018 Q1	$393K	Hold	13,276	–	–	0.29%	83
2017 Q4	$456K	Buy	+13,276	New	+$448K	0.33%	74

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Unison Advisors's MYGN Position: Q3 2019 in Review

Unison Advisors sold out of Myriad Genetics (MYGN) in Q3 2019, closing a stake of 13,276 shares — an estimated $369K sold.

Unison Advisors first reported a position in MYGN in Q4 2017 and held it in 7 quarters. The position peaked at $611K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Unison Advisors reported no remaining Myriad Genetics position as of Q3 2019 after selling out during the quarter.
Unison Advisors sold 13,276 Myriad Genetics shares in Q3 2019, an estimated $369K.
Unison Advisors first reported a position in Myriad Genetics in Q4 2017 and held it in 7 quarters.
Unison Advisors's Myriad Genetics position peaked at $611K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Unison Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.